Pharmacometrics and systems pharmacology of immune checkpoint inhibitor nivolumab in cancer translational medicine

Sujit Nair

Abstract


Nivolumab, a fully human immunoglobulin G4 (IgG4) monoclonal antibody (mAb) that targets the programmed cell death-1 (PD-1) inhibitory receptor expressed on lymphocytes and dendritic cells, has been approved for metastatic melanoma, advanced squamous non-small cell lung cancer (NSCLC) and metastatic renal cell carcinoma. In this review, pharmacology and pharmacometrics systems of this immunopharmaceutical are discussed. Mechanistic actions of T-cell biology with respect to both “priming phase” (anti-cytotoxic T-lymphocyte associated antigen 4 (anti-CTLA-4) mAb; ipilimumab) and “effector phase” (anti-PD-1 mAb; nivolumab) was discussed, respectively. Key pharmacometric variables in anticancer efficacy of nivolumab such as target engagement, metabolism, pharmacology systems and clearance are elucidated with an emphasis on current knowledge from pre-clinical as well as phase 1, 2 and 3 clinical trials information, including the data presented at the American Society of Clinical Oncology (ASCO) 2015 and European Cancer Congress 2015. Nivolumab biomarkers, safety, and synergistic combination immunotherapies are delineated. Nivolumab, administered via intravenous infusion, has an acceptable safety profile and good efficacy. Indeed, the way forward to leverage maximum benefits for the cancer patient may be to synergize anti-PD-1 blockade with complementary targets in immune checkpoint pathways or other oncogenic signal transduction pathways. The encouraging results with nivolumab lend credence to the promise of immune checkpoint blockade as a therapeutic strategy that has been come-of-age in clinical oncology. Of necessity, the burden of “financial toxicity” on cancer patients and families must be factored in considering nivolumab therapy. The problem of ligand PD-L1 being a weak biomarker in clinical practice was discussed. Appropriate patient selection methods including immunopharmacogenomics may be used to identify those patients who are most likely to benefit from anti-PD-1 therapy. Taken together, the potential success of nivolumab strengthens the case for accelerated development of immunopharmaceuticals and basic drug discovery in oncology, and potentially non-oncology indications, by stakeholders such as clinical oncologists, pharmacists and scientists in academia and the pharmaceutical industry in a concerted fashion.

Keywords


Nivolumab; PD-1; cancer; biomarkers; pharmacometrics; systems pharmacology; pharmacokinetics; T-cell; translational medicine

Full Text:

PDF

References


Nicodemus CF. Antibody-based immunotherapy of solid cancers: Progress and possibilities. Immunotherapy 2015; 7(8): 923–939. doi: 10.2217/imt.15.57.

Buqué A, Bloy N, Aranda F, Castoldi F, Eggermont A, Cremer I, Fridman WH, Fucikova J, Gallon J, Marabelle A, Spisek J, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Immunomodulatory monoclonal antibodies for oncological indications. Oncoimmunology 2015; 4(4): e1008814. doi: 10.1080/2162402X.2015.1008814.

Perez-Gracia JL, Labiano S, Rodriguez-Ruiz ME, Sanmamed MF, Melero I. Orchestrating immune check-point blockade for cancer immunotherapy in combinations. Curr Opin Immunol 2014; 27: 89–97. doi: 10.1016/j.coi.2014.01.002.

Sznol M, Longo DL. Release the hounds! Activating the T-cell response to cancer. N Engl J Med 2015; 372(4): 374–375. doi: 10.1056/NEJMe1413488.

Heigener D, Reck M. Exploring the potential of immuno-oncology-based treatment for patients with non-small cell lung cancer. Expert Rev Anticancer Ther 2015; 15(1): 69–83. doi: 10.1586/14737140.2015. 957187.

Faghfuri E, Faramarzi MA, Nikfar S, Abdollahi M. Nivolumab and pembrolizumab as immune-modulating monoclonal antibodies targeting the PD-1 receptor to treat melanoma. Expert Rev Anticancer Ther 2015; 15(9): 981–993. doi: 10.1586/14737140.2015.1074862.

Massari F, Santoni M, Ciccarese C, Santini D, Alfieri S, Martignoni G, Brunelli M, Piva F, Berardi R, Montironi R, Porta C, Cascinu S, Tortora G. PD-1 blockade therapy in renal cell carcinoma: current studies and future promises. Cancer Treat Rev 2015; 41(2): 114–121. doi: 10.1016/j.ctrv.2014.12.013.

Cheng X, Veverka V, Radhakrishnan A, Waters LC, Muskett FW, Morgan Sara, Huo J, Yu C, Evans EJ, leslie AJ, Griffiths M, Stubberfield C, Griffin R, Henry AJ, Jansson A, Ladbury JE, Ikemizu S, Carr MD, Davis SJ. Structure and interactions of the human programmed cell death 1 receptor. J Biol Chem 2013; 288(17): 11771–11785. doi: 10.1074/jbc.M112.448126.

Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig J, Shindyalov IN, Bourne PE. The protein data bank. Nucleic Acids Res 2000; 28(1): 235–242. doi: 10.1093/nar/28.1.235.

Berman H, Henrick K, Nakamura H. Announcing the worldwide protein data bank. Nat Struct Biol 2003; 10(12): 980. doi: 10.1038/nsb1203-980.

Wolchok JD. PD-1 blockers. Cell 2015; 162(5): 937. doi: 10.1016/j.cell.2015.07.045.

Swanson MS, Sinha UK. Rationale for combined blockade of PD-1 and CTLA-4 in advanced head and neck squamous cell cancer-review of current data. Oral Oncol 2015; 51(1): 12–15. doi: 10.1016/j.oraloncology. 2014. 10.010.

Madureira P, de Mello RA, de Vasconcelos A, Zhang Y. Immunotherapy for lung cancer: For whom the bell tolls? Tumour Biol 2015; 36(3): 1411–1422. doi: 10.1007/ s13277-015-3285-6.

Homet Moreno B, Ribas A. Anti-programmed cell death protein-1/ligand-1 therapy in different cancers. Br J Cancer 2015; 112(9): 1421–1427. doi: 10.1038/bjc.2015. 124.

Bayless H, Schneider S. Nivolumab: Immunotherapy in malignant melanoma. Clin J Oncol Nurs 2015; 19(4): 430–432. doi: 10.1188/15.CJON.430-432.

Wang C, Thudium KB, Han M, Wang XT, Huang H, Feingersh D, Garcia C, Wu Y, Kuhne M, Srinivasan M, Wong S, Garner N, Leblanc H, Bunch RT, Blanset D, Selby MJ, Korman AJ. In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates. Cancer Immunol Res 2014; 2(9): 846–856. doi: 10.1158/2326-6066.CIR-14-0040.

Wolchok JD, Saenger Y. The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation. Oncologist 2008; 13 Suppl 4: 2–9. doi: 10.1634/theoncologist.13-S4-2.

Callahan MK, Wolchok JD. At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy. J Leukoc Biol 2013; 94(1): 41–53. doi: 10.1189/jlb.1212631.

Ott PA, Hodi FS, Robert C. CTLA-4 and PD-1/PDL1 blockade: New immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin Cancer Res 2013; 19(19): 5300–5309. doi: 10.1158/1078- 0432.CCR-13-0143.

Novakovic BJ. Checkpoint inhibitors in Hodgkin lymphoma. Eur J Haematol 2015. doi: 10.1111/ejh.12697.

Eggermont AMM, Maio M, Robert C. Immune checkpoint inhibitors in melanoma provide the cornerstones for curative therapies. Semin Oncol 2015; 42(3): 429–435. doi: 10.1053/j.seminoncol.2015.02.010.

Robert C, Long GV, Brady B, Dutriaux C, Maio M,. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015; 372(4): 320–330. doi: 10.1056/NEJMoa1412082.

Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, Schuster SJ, Millenson MM, Cattry D, Freeman GJ, Rodig SJ, Chapuy B, Ligon AH, Zhu L, Grosso JF, Kim SY, Timmerman JM, Shipp MA, Armand P. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 2015; 372(4): 311–319. doi: 10.1056/NEJMoa1411087.

Lipson EJ, Sharfman WH, Drake CG, Wollner I, Taube JM, Anders RA, Xu H, Yao S, Pons A, Chen L, Pardoll DM, Brahmer JR, Topalian SL. Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Cancer Res 2013; 19(2): 462–468. doi: 10.1158/1078-0432.CCR-12-2625.

Davar D, Socinski MA, Dacic S, Burns TF. Near complete response after single dose of nivolumab in patient with advanced heavily pre-treated KRAS mutant pulmonary adenocarcinoma. Exp Hematol Oncol 2015; 4: 34. doi: 10.1186/s40164-015-0029-7.

Chen J, Jiang CC, Jin L, Zhang XD. Regulation of PD-L1: A novel role of pro-survival signalling in cancer. Ann Oncol 2016; 00: 1–8. doi: 10.1093/annonc/mdv615.

Zhang J, Gao J, Li Y, Nie J, Dai L, Hu W, Chen X, Han J, Ma X, Tian G, Wu D, Shen L, Fang J. Circulating PD-L1 in NSCLC patients and the correlation between the level of PD-L1 expression and the clinical characteristics. Thorac Cancer 2015; 6(4): 534–538. doi: 10.1111/1759-7714.12247.

Gowrishankar K, Gunatilake D, Gallagher SJ, Tiffen J, Rizos H, Hersey P. Inducible but not constitutive expression of PD-L1 in human melanoma cells is dependent on activation of NF-κB. PLoS One 2015; 10(4): e0123410. doi: 10.1371/journal.pone.0123410.

Bellucci R, Martin A, Bommarito D, Wang K, Hansen SH, Freeman GJ, Ritz J. Interferon-γ-induced activation of JAK1 and JAK2 suppresses tumor cell susceptibility to NK cells through upregulation of PD-L1 expression. Oncoimmunology 2015; 4(6): e1008824. doi: 10.1080/2162402X.2015.1008824.

Carbotti G, Barisione G, Airoldi I, Mezzanzanica D, Bagnoli M, Ferrero S, Petretto A, Fabbi M, Ferrini S. IL-27 induces the expression of IDO and PD-L1 in human cancer cells. Oncotarget 2015; 6(41): 43267–43280. doi: 10.18632/oncotarget.6530.

Atefi M, Avramis E, Lassen A, Wong DJL, Robert L, Foulad D, Cerniglia M, Titz B, Chodon T, Graeber TG, Comin-Anduix B, Ribas A. Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma. Clin Cancer Res 2014; 20(13): 3446–3457. doi: 10.1158/1078-0432.CCR-13-2797.

Lastwika KJ, Wilson W, Li QK, Norris J, Xu H, Ghazarian SR, Kitagawa H, Kawabata S, Taube JM, Yao S, Liu LN, Gills JJ, Dennis PA. Control of PD-L1 expression by oncogenic activation of the AKT/mTOR pathway in non-small cell lung cancer. Cancer Res 2015; 76(2): 227–238. doi: 10.1158/0008-5472.CAN-14-3362.

Das R, Verma R, Sznol M, Boddupalli CS, Gettinger SN, Kluger H, Callahan M, Wolchok JD, Halaban R, Dhodapkar MV, Dhodapkar KM. Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo. J Immunol 2015; 194(3): 950–959. doi: 10.4049/jimmunol.1401686.

Haanen JBAG, van Thienen H, Blank CU. Toxicity patterns with immunomodulating antibodies and their combinations. Semin Oncol 2015; 42(3): 423–428. doi: 10.1053/j.seminoncol.2015.02.011.

Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, Chen L, Pardoll DM, Topalian SL, Anders RA. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res 2014; 20(19): 5064– 5074. doi: 10.1158/1078-0432.CCR-13-3271.

Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, Biedrzycki B, Donehower RC, Zaheer A, Fisher GA, Crocenzi TS, Lee JJ, Duffy SM, Goldberg RM, de la Chapelle A, Koshiji M, Bhaijee F, Huebner T, Hruban RH, Wood LD, Cuka N, Pardoll DM, Papadopoulos N, Kinzler KW, Zhou S, Cornish TC, Taube JM, Anders RA, Eshleman JR, Vogelstein B, Diaz LA Jr. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015; 372(26): 2509–2520. doi: 10.1056/NEJMoa1500596.

Eroglu Z, Kim DW, Johnson DB, Algazi AP, Muhnoz RR, Liniker E, Kong B, Khurana N, Chmielowski B, Sosman JA, Scolyer RA, Carlino MS, Postow MA, Hwu WJ, Long GV, Ribas A. Response to anti-PD1/PDL1 therapy in patients with metastatic desmoplastic melanoma. 2015 ASCO Annual Meeting. Abstract Number 9011; 2015 May. Available from: http://meetinglibrary.asco.org/content/148604-156.

European Medicines Agency - Committee for Medicinal Products for Human Use (CHMP). Nivolumab BMS public assessment report. EMA/CHMP/392114/2015. London, United Kingdom: 2015. p. 1–108. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human /003840/WC500190651.pdf.

Meibohm B. Chapter 5: pharmacokinetics and pharmacodynamics of peptide and protein therapeutics. In: Crommelin DJA, Sindelar RD, Meibohm B, (editors). Pharmaceutical biotechnology: fundamentals and applications. 4th ed. New York: Springer-Verlag; 2013. p. 101–132. doi: 10.1007/978-1-4614-6486-0.

Cao Y, Jusko WJ. Survey of monoclonal antibody disposition in man utilizing a minimal physiologically-based pharmacokinetic model. J Pharmacokinet Pharmacodyn 2014; 41(6): 571–580. doi: 10.1007/s10928-014- 9374-0.

Sanmamed MF, Rodriguez I, Schalper KA, Oñate C, Azpilikueta A, Rodriguez-Ruiz ME, Morales-Kastresana A, Labiano S, Pérez-Gracia JL, Martín-Algarra S, Alfaro C, Mazzolini G, Sarno F, Hidalgo M, Korman AJ, Jure-Kunkel M, Melero. Nivolumab and urelumab enhance antitumor activity of human T lymphocytes engrafted in Rag2-/-IL2Rγnull immunodeficient mice. Cancer Res 2015; 75(17): 3466–3478. doi: 10.1158/0008-5472.CAN-14-3510.

Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, Stankevich E, Pons A, Salay TM, McMiller TL, Gilson MM, Wang C, Selby M, Taube JM, Anders R, Chen L, Korman AJ, Pardoll DM, Lowy I, Topalian SL. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: Safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010; 28(19): 3167–3175. doi: 10.1200/JCO.2009.26.7609.

Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366(26): 2443–2454. doi: 10.1056/NEJMoa1200690.

Brahmer JR, Tykodi SS, Chow LQM, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, Pitot HC, Hamid O, Bhatia S, Martins R, Eaton K, Chen S, Salay TM, Alaparthy S, Grosso JF, Korman AJ, Parker SM, Agrawal S, Goldberg SM, Pardoll DM, Gupta A, Wigginton JM. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366(26): 2455–2465. doi: 10.1056/NEJMoa1200694.

Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, Linette GP, Meyer N, Giguere JK, Agarwala SS, Shaheen M, Ernstoff MS, Minor D, Salama AK, Taylor M, Ott PA, Rollin LM, Horak C, Gagnier P, Wolchok JD, Hodi FS. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 2015; 372(21): 2006–2017. doi: 10.1056/NEJMoa1414428.

McDermott DF, Drake CG, Sznol M, Choueiri TK, Powderly JD, Smith DC, Brahmer JR2, Carvajal RD, Hammers HJ, Puzanov I, Hodi FS, Kluger HM, Topalian SL, Pardoll DM, Wigginton JM, Kollia GD, Gupta A, McDonald D, Sankar V, Sosman JA, Atkins MB. Survival, durable response, and long-term safety in patients with previously treated advanced renal cell carcinoma receiving nivolumab. J Clin Oncol 2015; 33(18): 2013–2020. doi: 10.1200/JCO.2014.58.1041.

Gettinger SN, Horn L, Gandhi L, Spigel DR, Anotonia SJ, Rizvi NA, Powderly JD, Heist RS, Carvajal RD, Jackman DM, Sequist LV, Smith DC, Leming P, Carbone DP, Pinder-Schenck MC, Topalian SL, Hodi FS, Sosman JA, Sznol M, McDermott DF, Pardoll DM, Sankar V, Ahlers CM, Salvati M, Wigginton JM, Hellmann MD, Kollia GD, Gupta AK, Brahmer JR. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 2015; 33(18): 2004–2012. doi: 10.1200/JCO.2014.58.3708.

Weber JS, Kudchadkar RR, Yu B, Gallenstein D, Horak CE, Inzunza HD, Zhao X, Martinez AJ, Wang W, Gibney G, Kroeger J, Eysmans C, Sarnaik AA, Chen YA. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. J Clin Oncol 2013; 31(34): 4311–4318. doi: 10.1200/JCO.2013.51.4802.

Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K, Burke MM, Caldwell A, Kronenberg SA, Agunwamba BU, Zhang X, Lowy I, Inzunza HD, Feely W, Horak CE, Hong Q, Korman AJ, Wigginton JM, Gupta A, Sznol M. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013; 369(2): 122–133. doi: 10.1056/NEJMoa1302369.

Hamanishi J, Mandai M, Ikeda T, Minami M, Kawaguchi A, Murayama T, Kanai M, Mori Y, Matsumoto S, Chikuma S, Matsumura N, Abiko K, Baba T, Yamaguchi K, Ueda A, Hosoe Y, Morita S, Yokode M, Shimizu A, Honjo T, Konishi I. Safety and antitumor activity of anti-pd-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer. J Clin Oncol 2015; 33(34): 4015–4022. doi: 10.1200/JCO.2015.62.3397.

Rizvi NA, Mazieres J, Planchard D, Stinchcombe TE, Dy GK, Antonia SJ, Horn L, Lena H, Minenza E, Mennecier B, Otterson GA, Campos LT, Gandara DR, Levy BP, Nair SG, Zalcman G, Wolf J, Souquet PJ, Baldini E, Cappuzzo F, Chouaid C, Dowlati A, Sanborn R, Lopez-Chavez A, Grohe C, Huber RM, Harbison CT, Baudelet C, Lestini BJ, Ramalingam SS. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): A phase 2, single-arm trial. Lancet Oncol 2015; 16(3): 257–265. doi: 10.1016/S1470-2045(15)70054-9.

Motzer RJ, Rini BI, McDermott DF, Redman BG, Kuzel TM, Harrison MR, Vaishampayan UN, Drabkin HA, George S, Logan TF, Margolin KA, Plimack ER, Lambert AM, Waxman IM, Hammers HJ. Nivolumab for metastatic renal cell carcinoma: Results of a randomized phase II trial. J Clin Oncol 2015; 33(13): 1430–1437. doi: 10.1200/JCO.2014.59.0703.

Brower V. Checkpoint blockade immunotherapy for cancer comes of age. J Natl Cancer Inst 2015; 107(3): djv069. doi: 10.1093/jnci/djv069.

Alexander W. Meeting highlights: European Cancer Congress. Pharm Ther 2015; 40(11): 769–771.

Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, Brahmer JR, Lawrence DP, Atkins MB, Powderly JD, Leming PD, Lipson EJ, Puzanov I, Smith DC, Taube JM, Wigginton JM, Kollia GD, Gupta A, Pardoll DM, Sosman JA, Hodi FS. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014; 32(10): 1020–1030. doi: 10.1200/JCO.2013.53.0105.

Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, Ferrucci PF, Hill A, Wagstaff J, Carlino MS, Haanen JB, Maio M, Marquez-Rodas I, McArthur GA, Ascierto PA, Long GV, Callahan MK, Postow MA, Grossmann K, Sznol M, Dreno B, Bastholt L, Yang A, Rollin LM, Horak C, Hodi FS, Wolchok JD. Combined Nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015; 373(1): 23–34. doi: 10.1056/NEJMoa1504030.

Weber JS, D'Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, Hoeller C, Khushalani NI, Miller WH Jr, Lao CD, Linette GP, Thomas L, Lorigan P, Grossmann KF, Hassel JC, Maio M, Sznol M, Ascierto PA, Mohr P, Chmielowski B, Bryce A, Svane IM, Grob JJ, Krackhardt AM, Horak C, Lambert A, Yang AS, Larkin J. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): A randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2015; 16(4): 375–384. doi: 10.1016/S1470-2045(15)70076-8.

Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardet WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, Waterhouse D, Ready N, Gainor J, Arén Frontera O, Havel L, Steins M, Garassino MC, Aerts JG, Domine M, Paz-Ares L, Reck M, Baudelet C, Harbison CT, Lestini B, Spigel DR. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015; 373(2): 123–135. doi: 10.1056/NEJMoa1504627.

Kazandjian D, Khozin S, Blumenthal G, Zhang L, Tang S, Libeg M, Kluetz P, Sridhara R, Keegan P, Pazdur R. Benefit-risk summary of nivolumab for patients with metastatic squamous cell lung cancer after platinum-based chemotherapy: A report from the us food and drug administration. JAMA Oncol 2016; 2(1): 118–122. doi: 10.1001/jamaoncol.2015.3934.

Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, Castellano D, Choueiri TK, Gurney H, Donskov F, Bono P, Wagstaff J, Gauler TC, Ueda T, Tomita Y, Schutz FA, Kollmannsberger C, Larkin J, Ravaud A, Simon JS, Xu LA, Waxman IM, Sharma P, CheckMate 025 Investigators. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 2015; 373(19): 1803–1813. doi: 10.1056/NEJMoa1510665.

Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, Barlesi F, Kohlhäufl M, Arrieta O, Burgio MA, Fayette J, Lena H, Poddubskaya E, Gerber DE, Gettinger SN, Rudin CM, Rizvi N, Crinò L, Blumenschein GR Jr, Antonia SJ, Dorange C, Harbison CT, Graf Finckenstein F, Brahmer JR. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 2015; 373(17): 1627–1639. doi: 10.1056/NEJMoa1507643.

Starr P. Nivolumab beats docetaxel as second-line therapy for patients with NSCLC. Am Health Drug Benefits 2015; 8(Spec Issue): 1–18.

Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Ferrucci PF, Smylie M, Dummer R, Hill AG, Haanen JBAG, Maio M, McArthur GA, Yang A, Rollin L, Horak CE, Larkin JMG, Hodi FS. Efficacy and safety results from a phase III trial of nivolumab alone or combined with ipilimumab versus ipilimumab alone in treatment-naive patients with advanced melanoma (CheckMate 067). 2015 ASCO Annual Meeting. Abstract LBA1; 2015 May. Available from: http://meetinglibrary.asco.org/content/144621-156.

Raedler LA. Opdivo (nivolumab): Second PD-1 inhibitor receives FDA approval for unresectable or metastatic melanoma. Am Health Drug Benefits 2015; 8(Spec Feature): 180–183.

Shirai T, Sano T, Kamijo F, Saito N, Miyake T, Kodaira M, Katoh N, Nishie K, Okuyama R, Uhara H. Acetylcholine receptor binding antibody-associated myasthenia gravis and rhabdomyolysis induced by nivolumab in a patient with melanoma. Jpn J Clin Oncol 2016; 46(1): 86–88. doi: 10.1093/jjco/hyv158.

Freeman-Keller M, Kim Y, Cronin H, Richards A, Gibney G, Weber JS. Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes. Clin Cancer Res 2015; 1–9. doi: 10.1158/1078-0432.CCR-15-1136.

Maurice C, Schneider R, Kiehl TR, Bavi P, Roehrl MH, Mason WP, Hogg D. Subacute CNS demyelination after treatment with nivolumab for melanoma. Cancer Immunol Res 2015; 3(12): 1299–1302. doi: 10.1158/2326-6066.CIR-15-0141.

Kato Y, Otsuka A, Miyachi Y, Kabashima K. Exacerbation of psoriasis vulgaris during nivolumab for oral mucosal melanoma. J Eur Acad Dermatol Venereol 2015. doi: 10.1111/jdv.13336.

Matsumura N, Ohtsuka M, Kikuchi N, Yamamoto T. Exacerbation of psoriasis during nivolumab therapy for metastatic melanoma. Acta Derm Venereol 2016; 96(2): 259–260. doi:10.2340/00015555-2212.

Imafuku K, Yoshino K, Ishiwata K, Otobe S, Tsuboi S, Tsuboi S1, Ohara K1, Hata H. Severe rash associated with vemurafenib administration following nivolumab therapy. J Eur Acad Dermatol Venereol 2015. doi: 10.1111/jdv.13331.

de Velasco G, Bermas B, Choueiri TK. Auto-immune arthropathy and uveitis as complications from PD-1 inhibitor. Arthritis Rheumatol 2016; 68(2): 556–557. doi: 10.1002/art.39406.

Abdel-Rahman O, ElHalawani H, Fouad M. Risk of cutaneous toxicities in patients with solid tumors treated with immune checkpoint inhibitors: A meta-analysis. Future Oncol 2015; 11(17): 2471–2484. doi: 10.2217/ fon.15.118.

Somasundaram R, Herlyn M. Nivolumab in combination with ipilimumab for the treatment of melanoma. Expert Rev Anticancer Ther 2015; 15(10): 1135–1141. doi: 10.1586/14737140.2015.1093418.

Berman D, Korman A, Peck R, Feltquate D, Lonberg N, Canetta R. The development of immunomodulatory monoclonal antibodies as a new therapeutic modality for cancer: the Bristol-Myers Squibb experience. Pharmacol Ther 2015; 148: 132–153. doi: 10.1016/j.pharmthera.2014.11.017.

Melero I, Berman DM, Aznar MA, Korman AJ, Gracia JLP, Haanen J. Evolving synergistic combinations of targeted immunotherapies to combat cancer. Nat Rev Cancer 2015; 15(8): 457–472. doi: 10.1038/nrc3973.

Mahoney KM, Rennert PD, Freeman GJ. Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov 2015; 14(8): 561–584. doi: 10.1038/nrd4591.

Sullivan RJ, Lorusso PM, Flaherty KT. The intersection of immune-directed and molecularly targeted therapy in advanced melanoma: Where we have been, are, and will be. Clin Cancer Res 2013; 19(19): 5283–5291. doi: 10.1158/1078-0432.CCR-13-2151.

Ascierto PA, Marincola FM, Atkins MB. What's new in melanoma? Combination! J Transl Med 2015; 13: 213. doi: 10.1186/s12967-015-0582-1.

Fu J, Malm IJ, Kadayakkara DK, Levitsky HY, Pardoll D, Kim YJ. Preclinical evidence that PD1 blockade cooperates with cancer vaccine TEGVAX to elicit regression of established tumors. Cancer Res 2014; 74(15): 4042–4052. doi: 10.1158/0008-5472.CAN-13-2685.

Fujimura T, Furudate S, Kakizaki A, Kambayashi Y, Haga T, Hashimoto A, Aiba S. Contact immunotherapy enhances the therapeutic effects of nivolumab in treating in-transit melanoma: two cases reports. J Dermatol 2015; 42: 1–4. doi: 10.1111/ 1346-8138.13229.

Zafar SY. Financial Toxicity of cancer care: It's time to intervene. J Natl Cancer Inst 2016; 108(5): djv370. doi: 10.1093/jnci/djv370.

Tucker-Seeley RD, Yabroff KR. Minimizing the “financial toxicity” associated with cancer care: advancing the research agenda. J Natl Cancer Inst 2016; 108(5): djv410. doi: 10.1093/jnci/djv410.

Schilsky RL, Wehrwein P. Gains against cancer, but enter 'financial toxicity'. Manag Care 2015; 24(10): 46–47, 52–54.

Choudhury N, Nakamura Y. The importance of immunopharmacogenomics in cancer treatment: Patient selection and monitoring for immune checkpoint antibodies. Cancer Sci 2015. doi: 10.1111/cas.12862.

Phillips T, Simmons P, Inzunza HD, Cogswell J, Novotny J Jr, Taylor C, Zhang X. Development of an automated PD-L1 immunohistochemistry (IHC) assay for non-small cell lung cancer. Appl Immunohistochem Mol Morphol 2015; 23(8): 541–549. doi: 10.1097/PAI.0000000000000256.

Powles T, Staehler M, Ljungberg B, Bensalah K, Canfield SE, Dabestani S, Giles R, Hofmann F, Hora M, Kuczyk MA, Lam T, Marconi L, Merseburger AS, Volpe A, Bex A. Updated EAU guidelines for clear cell renal cancer patients who fail VEGF targeted therapy. Eur Urol 2016; 69(1): 4–6. doi: 10.1016/j.eururo.2015.10.017.




DOI: http://dx.doi.org/10.30564/amor.v2i1.28

Refbacks

  • There are currently no refbacks.


Copyright (c) 2018 Sujit Nair

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.